MediWound (NASDAQ:MDWD) Share Price Crosses Above 50-Day Moving Average – Should You Sell?

Shares of MediWound Ltd. (NASDAQ:MDWD) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $18.14 and traded as high as $18.17. MediWound shares last traded at $17.62, with a volume of 159,203 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MDWD shares. HC Wainwright restated a “buy” rating and set a $36.00 target price (up previously from $31.00) on shares of MediWound in a research report on Friday, November 21st. Wall Street Zen upgraded MediWound from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, MediWound presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.50.

MediWound Stock Performance

The stock has a market cap of $226.24 million, a P/E ratio of -9.27 and a beta of 0.13. The company has a 50-day simple moving average of $18.14 and a 200-day simple moving average of $18.11.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.57. The company had revenue of $5.43 million for the quarter, compared to analysts’ expectations of $6.56 million. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%. As a group, sell-side analysts expect that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its position in MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 723 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Rhumbline Advisers increased its position in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 481 shares during the period. Finally, Hudson Bay Capital Management LP bought a new stake in MediWound during the 3rd quarter worth about $180,000. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.